Board director Kirk Perry has been named interim CEO while the company undergoes a strategic review aimed at simplifying its operations and strengthening performance after ... The post Kenvue stock ...

Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

Kenvue Inc (NYSE:KVUE) saw its stock rise 5.3% following a surprise leadership shakeup and confirmation of a broader strategic reassessment aimed at enhancing shareholder returns. The company ...

Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

Alongside the leadership change, Kenvue revealed that its Board had previously initiated a comprehensive review of strategic alternatives and established a Strategic Review Committee. The review will ...

Shares of Kenvue Inc. KVUE rose 1.53% to $21.85 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the Dow Jones Industrial Average DJIA remaining mostly ...

Shares of Kenvue Inc. KVUE slid 2.68% to $21.45 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.13% to 5,976.97 and Dow ...